Stage
No active trials
Next date
None yet
Trials
0 active
4 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Patients will receive a fixed dose of 750mg as 1-hour IV infusion”In the company’s words, NCT05321147 on ClinicalTrials.gov
- Tested for
- Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome, Cutaneous T-Cell Lymphoma, Peripheral T Cell Lymphoma
- Main trialPhase 2
- “This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.”In the company’s words, NCT03902184 on ClinicalTrials.gov
- Other names
- IPH4102
Other drugs for Lymphoma, T-Cell
- XNW5004Evopoint Biosciences Inc. · Phase 3
- GolidocitinibDizal Pharmaceuticals · Phase 3
- SoquelitinibCorvus Pharmaceuticals, Inc. · Phase 3
- Liposomal mitoxantrone hydrochlorideCSPC · Phase 3
- DuvelisibSecuraBio · Phase 3
- TR115Tarapeutics Science Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 8 Jan 2026 | IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma | |
| Phase 1Completed | Apr 2020 | Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) | |
| Phase 1Completed | 19 Nov 2023 | Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 | |
| Phase 2Ended | not given | KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026